Article

Evidence-based ophthalmology

Why it is that ophthalmologists who read the same papers in the same journals have such widely varying approaches?

During a recent conference, I had the chance to get together with three colleagues from around the world. It was after 5 p.m. The lectures were over. We were sitting in a café enjoying the fruity adult beverage for which the host country is justly famous.

I don’t like to brag, but my ophthalmologist friends are fabulously successful (by any measure) and extremely intelligent and respected physicians. They live thousands of miles apart. Among the four of us seated at the table, six languages were spoken. All of them read and publish in the English language ophthalmology journals. We alternated back and forth between two languages as we sipped our cocktails and this truth serum began to flow through our veins.
 

Three different regimens

Somehow the topic of adenovirus conjunctivitis came up. I asked each of my colleagues how they treated that condition. What I heard surprised me.

One of my colleagues is impressed with the literature supporting a role for povidone iodine. He treats patients presenting with EKC with that agent, then has them escorted from his office while staff carefully wipe down everything the patient might have touched while present. He is careful to avoid the use of steroids, having been taught that they prolong the course of the disease. He believes his therapy shortens the course of the disease substantially.

Another colleague has a very different regimen. He gives every patient a topical nonsteroidal agent plus an intramuscular injection of a potent and long acting steroid. He believes his approach maximizes patient comfort and reduced redness and swelling. Patients can function and are grateful to have few symptoms.

My third colleague gives supportive therapy only, recommends transmission precautions, and reserves topical steroids for only the very severely affected patients.

Why three different regimens?

 

Over a second delicious beverage, we discussed why it is that ophthalmologists who read the same papers in the same journals have such widely varying approaches to the management of a very common eye problem.

Not everyone gives the same credence to the same publications. Some ophthalmologists train with professors who are vehemently opposed to the use of corticosteroids while others had professors who used steroids frequently.

One colleague told an amusing story; his professor forbade the use of steroids by residents for patients in the university clinic but used them liberally in his private practice.

“I have to keep my private patients comfortable and happy,” he confided to his junior colleague.

The variation in practice among very well trained ophthalmologists frequently surprises me, given that we all acknowledge the importance of scientific evidence to guide our practice and read the same journals.

I dream of a future time when every patient with a certain problem receives the same effective treatment based upon the most current scientific knowledge, no matter which doctor he or she happens to see.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.